Emanate Biomedical has received U.S. Food and Drug Administration 510(k) clearance for Perio Pods, a periodontal wound dressing consisting of single-use, patient-matched dental trays preloaded with engineered hydrogel. The device is designed to protect injured periodontal tissue following nonsurgical procedures such as scaling and root planing -- a healing phase the company says has lacked a purpose-built, FDA-cleared, at-home solution despite roughly 31 million such procedures performed annually in the U.S.
Jarret Fass, Emanate's co-founder and CEO, said the clearance addresses a longstanding gap in protecting treated tissue during at-home healing. In a 45-patient randomized controlled trial at the ADA Forsyth Institute, Perio Pods was associated with significantly greater reductions in pocket depth and inflammatory markers versus debridement alone. The study, according to Emanate, was selected for oral presentation at the 2026 IADR General Session. A larger multicenter trial is underway through the McGuire Institute.
Custom-manufactured from a digital impression, Perio Pods is prescribed for at-home use twice daily for up to 15 days following treatment. Emanate, which has raised $11 million from Pierpoint Capital, is preparing for a phased U.S. launch in 2027, with practices already joining its Launch Partner Program.
